Completed PHASE1 INTERVENTIONAL 1-arm NCT00498979

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons

Sponsor: Case Comprehensive Cancer Center

Conditions Stage IV Melanoma

Interventions cisplatin dacarbazine recombinant interferon alfa-2b sodium stibogluconate vinblastine

Updated 7 times since 2017 Last updated: Jul 22, 2020 Started: May 31, 2007 Primary completion: May 31, 2010 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Stage IV Melanoma, this trial is completed. The trial is conducted by Case Comprehensive Cancer Center and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2020 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States